Administration of Antioxidant Vitamins Does Not Alter Plasma Fibrinolytic Activity in Subjects with Central Obesity

Summary

In vitro studies suggest that oxidized low density lipoprotein inhibits fibrinolysis by stimulating the production of plasminogen activator inhibitor -1 (PAI). We assessed the effects of dietary antioxidant vitamins for four weeks on three indices of copper mediated oxidation of very low and low density lipoproteins (VLDL+LDL) and plasma fibrinolytic activities in 15 male subjects with central obesity, a condition associated with increased PAI activity. Vitamin administration resulted in a decrease in production of thiobarbituric acid reactive substances from 29.3 ± 3.9 to 13.6 ± 3.5 nmoles/mg VLDL + LDL protein (mean ± SE, p <0.003), an increase in the lag phase of conjugated diene formation from 94.8 ± 5.5 to 225.0 ±31.9 min (p <0.001) and an increase in reactivity of lysine residues from 73.6% ± 4.8% to 86.8% ± 3.6% (p <0.034) demonstrating a reduction in the susceptibility of the lipoproteins to oxidation. However, antioxidant vitamins had no effect on plasma PAI activity, PAI antigen, tissue-type plasminogen activator activity and antigen, fibrinogen and fibrin degradation products. These results do not support the hypothesis that lipoprotein oxidation is a significant cause of impaired fibrinolysis in men with central obesity.

• References

• 1 Hamsten A, Walldius G, Szamosi A, Blombäck M, DeFaire U, Dahlen G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma, a risk factor for recurrent myocardial infarction. Lancet 1987; 01: 3-9
• 2 Nilsson T, Johnson O. The extrinsic fibrinolytic system in survivors of myocardial infarction. Throm Res 1987; 48: 621-640
• 3 Aznar J, Estelles A, Torino G, Sapena P, Tormo V, Blanch S, Espana F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59: 535-541
• 4 Schneider SH, Kim HC, Ruderman NB, Khachadurian KA. Impaired fibrinolytic responses to exercise in type 2 diabetes: effects of exercise and physical training. Metabolism 1988; 37: 924-929
• 5 Sundell I Birgitta, Nilsson TK, Hallmans G, Hellsten G, Dahlen GH. Inter relationships among plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein(a) and established cardiovascular risk factors in a North Swedish population. Atherosclerosis 1989; 80: 9-16
• 6 Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ, Serra dimigniA, Collen D. Plasma plasminogen activator-1 in angina pectoris. Arteriosclerosis 1989; 9: 362-367
• 7 Miller GJ. Lipoproteins and thrombosis: effects of lipid lowering. Curr OpinLipidol 1995; 06: 38-42
• 8 Vague P, Juhan-Vague I, Aillaud M, Badier C, viard R, Alessi M, Collen D. Correlation between blood fibrinolytic actvity, plasminogen activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-253
• 9 Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengbom L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor. Metabolism 1990; 39: 1044-1048
• 10 Cigolini M, Targher G, Bergamo AndriesIA, Tonoli M, Agostino G, De SandreG. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vase Biol 1996; 16: 368-374
• 11 Stout RW. Insulin and atheroma; 20 year perspective. Diabetes Care 1990; 13: 631-654
• 12 Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993; 13: 1865-1873
• 13 Hamsten A, Eriksson P, Karpe F, Silviera A. Relationships of thrombosis and fibrinolysis to atherosclerosis. Curr Opin LipidOl 1994; 05: 382-389
• 14 Witztum JL. Steinberg D: Roleof oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-1792
• 15 O'Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, LaFont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 1991; 11: 1821-1829
• 16 Chautan M, Latron Y, Anfosso F, Alessi MC, Lafont H, Juhan-Vague I, Nalbone G. Phosphotidylinositol turnover during stimulation of plasmino gen activatior inhibitor-1 secretion induced by oxidized low density lipo proteins in human endothelial cells. J. Lipid Res Lipid Res 1993; 34: 101-110
• 17 Rifici VA, Schneider SH, Khachadurian AK. Stimulation of low-density lipoprotein oxidation by insulin and insulin like growth factor I. Athero sclerosis 1994; 107: 99-108
• 18 Jessup W, Rankin S, De WhalleyC, Scott J. Leake DS: Alpha tocopherol consumption during during low density lipoprotein oxidation. Biochem J 1990; 265: 399-405
• 19 Dieber RothenederM, Puhl A, Waeg G, Striegel G, Esterbauer H. Effect of oral supplementation with D-alpha-tocopherol on the vitamin E content of human low density lipoproteins and resistanceto oxidation. J Lipid Res 1991; 32: 1325-1332
• 20 Jialal I, Grundy SM. Effect of dietary supplementation with alpha tocoph erol on the oxidative modification of low density lipoprotein. J Lipid Res 1992; 33: 899-906
• 21 Rifici VA, Khachadurian AK. Dietary supplementation with vitamins C and E inhibits in vitro oxidation of lipoproteins. J Am Coll Nutr 1993; 12: 631-637
• 22 Denson KW, Bowers EF. The determination of ascorbic acid in white blood cells. A comparison of WBC acorbic acid and phenolic acid excretion in elderlypatients. Clin Science 1961; 21: 157-161
• 23 Havel RJ, Eder AH, Bragdon JH. The distribution and chemical composi tion of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353
• 24 Hessler JR, Morel DW, Lewis LJ, Chisolm GM. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 1983; 03: 215-222
• 25 Steinbrecher UP, Witzum JL, Parthasarathy S, Steinberg D. Decrease in reactive amino acid groups during oxidation or endothelial cell modifica tion of LDL. Arteriosclerosis 1987; 07: 135-143
• 26 Esterbauer H, Striegel G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad Res Commun 1989; 06: 67-75
• 27 Stiko-Rahm A, Wiman B, Homsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-1073
• 28 Tremoli E, Camera M, Madema P, Sironi L, Prati S, Colli S, Piovella F, Bernini F, Corsini A, Mussoni L. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. Arterioscler Thromb 1993; 13: 338-346
• 29 Zavaroni I, Bonora E, Pagliara M, Dall’Aglio E, Luchetti L, Buonanno G, Bonati PA, Bergonzani M, Gnuda L, Passed M, Reaven GN. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320: 702-706
• 30 Schneider SH, Kim H. Exercise and fibrinolysis in diabetes mellitus, in. Devlin JT, Horton ES, Vranic M. (eds): Diabetes Mellitus and Exercise, Smith-Gordon/Nishimura. London/Niigata-Shi: 1992. pp. 231-246
• 31 Crutchley DJ, McPhee GV, Terris MF, Canossa-Terris MA. Levels of three hemostatic factors in relation to serum lipids. Arteriosclerosis 1989; 09: 934-939
• 32 Sironi L, Mussoni L, Prati L, Bal dassarre, Camera M, Banfi C, Tremoli E. Plasminogen activator inhibitor type-1 synthesis and mRNA are regulated by VLDL. Arterioscler Thromb Vase Biol 1996; 16: 89-96
• 33 Bröijersen A, Eriksson M, Wiman B, Angelin B, Hjemdahl P. Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. Arterioscler Thromb Vase Biol 1996; 16: 511-516